The therapeutic value of ACB1801-dependent increase of TAP1, TAP2, Tapasin and Lmp2 is underscored by clinical data showing that high expression levels of these proteins was observed in melanoma patients that respond to anti-PD-1 and associated with an improved survival of melanoma patients. This evidence concerns the gene PSMB9 and melanoma.